Company intelligence / Profile preview
Navipharm
Vietnamnavipharm.in ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Navipharm has multiple small molecule drug candidates in Phase 1 clinical trials targeting nervous system and cardiovascular diseases. Its Korean division has developed clinically tested duo-strain probiotics with commercial launches addressing allergic rhinitis, sleep/anxiety, liver health, and menopause-related symptoms.
- Therapeutic areas
- ImmunologyPsychiatryGastroenterologyCardiovascularNeurologyWomen's Health
- Modalities
- Small moleculeProbiotic-based therapy
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
No major global pharmaceutical partnerships publicly listed; the company engages in licensing deals and project management collaborations with clients globally.
Beyond the preview
Go deeper on Navipharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Navipharm.